Euroapi S.A. (OTCMKTS:EAPIF) Sees Significant Decline in Short Interest

Euroapi S.A. (OTCMKTS:EAPIF) saw a significant decline in short interest in February. As of February 13th, there was short interest totaling 28,212 shares, a decline of 38.9% from the January 29th total of 46,171 shares. Based on an average daily volume of 439 shares, the days-to-cover ratio is currently 64.3 days. Based on an average daily volume of 439 shares, the days-to-cover ratio is currently 64.3 days.

Euroapi Price Performance

Euroapi stock remained flat at C$2.54 during trading hours on Friday. The firm has a fifty day moving average of C$2.57 and a 200-day moving average of C$3.07. Euroapi has a 1 year low of C$2.46 and a 1 year high of C$3.74.

Analyst Upgrades and Downgrades

Separately, Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Euroapi in a research note on Thursday, January 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

About Euroapi

Euroapi is a standalone global active pharmaceutical ingredient (API) company formed in 2022 following its spin-off from the API division of a major multinational pharmaceutical group. The company focuses on the development, manufacturing and supply of a broad range of small-molecule APIs used in prescription drugs, over-the-counter products and vaccines. Its portfolio encompasses core areas such as semi-synthetic antibiotics (notably penicillins and cephalosporins), APIs for oncology, central nervous system disorders and cardiovascular therapies, as well as niche specialty ingredients.

Since its inception, Euroapi has pursued a growth strategy centered on innovation, capacity expansion and long-term partnerships with pharmaceutical customers.